Activators of peroxisome proliferator-activated receptor

Abstract

Activators of peroxisome proliferator-activated receptors comprising a polyprenyl compound, preferably (2E,4E,6E,10E)-3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaenoic acid, as an active ingredient, and medicaments for preventive and/or therapeutic treatment of hyperlipidemia, non-insulin dependent diabetes mellitus or the like comprising a polyprenyl compound as an active ingredient.

1 - 13 . (canceled)  
     
     
         14 . A medicament which comprises a polyprenyl compound as an active ingredient, wherein the medicament is associated with instructions to administer the medicament to prevent or treat at least one of hyperlipidemia and non-insulin dependent diabetes mellitus.  
     
     
         15 . The medicament of  claim 14 , wherein the polyprenyl compound comprises at least one of a polyprenylcarboxylic acid and an ester thereof.  
     
     
         16 . The medicament of  claim 14 , wherein the polyprenyl compound comprises 3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaenoic acid.  
     
     
         17 . A method of preventing or treating hyperlipidemia, wherein the method comprises administering a preventively or therapeutically effective amount of at least one polyprenyl compound to a patient in need thereof.  
     
     
         18 . The method of  claim 17 , wherein the at least one polyprenyl compound comprises at least one of a polyprenylcarboxylic acid and an ester thereof.  
     
     
         19 . The method of  claim 18 , wherein the at least one polyprenyl compound comprises 3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaenoic acid.  
     
     
         20 . The method of  claim 18 , wherein the at least one polyprenyl compound comprises (2E,4E,6E,10E)-3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaenoic acid.  
     
     
         21 . The method of  claim 17 , wherein the at least one polyprenyl compound is in an orally administrable form.  
     
     
         22 . A method of preventing or treating non-insulin dependent diabetes mellitus, wherein the method comprises administering a preventively or therapeutically effective amount of at least one polyprenyl compound to a patient in need thereof.  
     
     
         23 . The method of  claim 22 , wherein the at least one polyprenyl compound comprises at least one of a polyprenylcarboxylic acid and an ester thereof.  
     
     
         24 . The method of  claim 23 , wherein the at least one polyprenyl compound comprises 3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaenoic acid.  
     
     
         25 . The method of  claim 23 , wherein the at least one polyprenyl compound comprises (2E,4E,6E,10E)-3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaenoic acid.  
     
     
         26 . The method of  claim 22 , wherein the at least one polyprenyl compound is in an orally administrable form.  
     
     
         27 . A method of activating a peroxisome proliferator-activated receptor (PPAR), wherein the method comprises administering a PPAR activating amount of at least one polyprenyl compound to a patient in need of such activation.  
     
     
         28 . The method of  claim 27 , wherein the at least one polyprenyl compound comprises at least one of a polyprenylcarboxylic acid and an ester thereof.  
     
     
         29 . The method of  claim 28 , wherein the at least one polyprenyl compound comprises 3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaenoic acid.  
     
     
         30 . The method of  claim 28 , wherein the at least one polyprenyl compound comprises (2E,4E,6E, 10E)-3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaenoic acid.  
     
     
         31 . The method of  claim 27 , wherein the at least one polyprenyl compound is in an orally administrable form.  
     
     
         32 . The method of  claim 27 , wherein the PPAR comprises PPARα.  
     
     
         33 . The method of  claim 27 , wherein the PPAR comprises PPARγ.